Queen’s University is located in historic Kingston, on the shores of Lake Ontario, with easy access to Montreal, Toronto & Ottawa. This university city of approximately 150,000 offers a unique mix of year-round recreational, cultural and academic opportunities. Queen’s University is recognized nationally and internationally for the quality of its undergraduate and graduate programs, which attract outstanding students. It has a community spirit and amenities unmatched by any other Canadian university.

The Canadian Cancer Trials Group (CCTG) statistical and operations office, based at the Queen’s University Cancer Research Institute in Kingston, Ontario, is seeking a Physician trained in a cancer-related specialty to join our research group as a Senior Investigator in the Investigational New Drug (IND) Program.

CCTG is Canada’s largest academic cooperative group that conducts multi-centre cancer clinical trials nationally and internationally, spanning the continuum of phase I trials testing novel agents to large randomized controlled trials. Over 80 member institutions across Canada, ranging in size from major cancer centres to community hospitals, enroll patients on CCTG studies. Over 2,000 physicians, research nurses, data managers and pharmacists participate in the conduct of these trials. Between its inception in 1980 and 2019, the CCTG (formerly the NCIC Clinical Trials Group) has conducted more than 500 phase I to III trials that included 80,000 patients. The activities of its IND Program includes more than 200 phase I or II studies that included 6,000 patients. The CCTG statistical and operations office is responsible for all aspects of trial management and analysis conducted by the CCTG network.

Senior investigators based in the IND Program work with members of the investigational new drug and disease-specific scientific committees, which have national investigator leadership and membership, to develop and implement the CCTG clinical trials research agenda. Senior investigator responsibilities include development and refinement of trial questions, and oversight of trial development, conduct and analysis as part of the trial team. Senior investigators are also responsible for securing funding and investigations agents via grants and contract agreements to support the study conduct.

Candidates must have 3 to 5 years’ post-specialist training experience, expertise in developing and leading early phase investigational therapeutic trials, as well as specific training and/or experience in clinical methodology related to early phase experimental therapeutic trials. Experience in overseeing multi-centre clinical trials is an asset. Individuals with prior leadership experience in investigational drug trials may be considered for the position of co-Director of the IND Program. Candidates must have an MD or equivalent, have completed specialty training in an oncology-related discipline (i.e., medical, pediatric or hematologic-oncology), and be eligible for licensure by the College of Physicians and Surgeons of Ontario. Preference will be given to those who hold specialty training from the Royal College of Physicians and Surgeons of Canada or the American Board of Specialties. Strong written and verbal communication skills are required, as is the ability to work both independently and as part of a team. The potential for teaching and supervision of MD fellowships and/or graduate students should be demonstrated. Preference will be given to applicants who will contribute to education as part of their role description.

This will be a three-year Special Appointment in the Department of Oncology, Faculty of Health Sciences at Queen’s University, renewable at three-year intervals. Academic rank and salary will be commensurate with qualifications and experience. The successful applicant may also participate in the provision of outpatient oncology clinical care at the Cancer Centre of Southeastern Ontario/Kingston General Hospital.

The University invites applications from all qualified individuals. Queen’s is committed to employment equity and diversity in the workplace and welcomes applications from women, racialized/visible minorities, Indigenous/Aboriginal Peoples, persons with disabilities, and LGBTQ+ persons. All qualified candidates are encouraged to apply; however, in accordance with Canadian immigration requirements, Canadian citizens and permanent residents of Canada will be given priority.

To comply with federal laws, the University is obliged to gather statistical information as to how many applicants for each job vacancy are Canadian citizens / permanent residents of Canada. Applicants need not identify their country of origin or citizenship; however, all applications must include one of the following statements: “I am a Canadian citizen / permanent resident of Canada”; OR, “I am not a Canadian citizen / permanent resident of Canada”. Applications that do not include this information will be deemed incomplete.

Please reply with a curriculum vitae and a list of three potential referees, including their names, addresses and emails, to: Dr. Janet E Dancey, Director, Canadian Cancer Trials Group, Cancer Research Institute, 10 Stuart Street, Kingston, Ontario, Canada, K7L 3N6. Email: Jdancey@cctg.queensu.ca. Review of applications will begin on October 31, 2019 and continue until the position is filled.

The University will provide support in its recruitment processes to applicants with disabilities, including accommodation that takes into account an applicant’s accessibility needs. If you require accommodation during the interview process, please contact: Tracey St John (tstjohn@cctg.queensu.ca).